Incyte (INCY) Wells Fargo 21st Annual Healthcare Conference summary

Strategic priorities and growth outlook

• Focus on maintaining double-digit growth in the core business (excluding Jakafi) through 2029, targeting $3–4 billion by 2030, driven by new product launches.

• Pipeline execution is central to post-2029 recovery, aiming for a 15–20% five-year CAGR and $8–10 billion top-line potential, with five key assets expected to drive 80–90% of growth.

• Business development supplements internal innovation, with a disciplined approach to deals that fit strategic criteria.

• Transitioning from single-asset to franchise strategies in hematology and GI oncology for broader market impact.

Key pipeline assets and clinical updates

• G12D inhibitor program is advancing in pancreatic and colorectal cancers, with important efficacy and safety data to be presented at ESMO; expansion into adjuvant and combination settings is underway.

• TGF-beta by PD-1 bispecific is a high-risk, high-reward asset in frontline MSS colorectal cancer, showing promising single-agent and combination activity, with phase III and adjuvant studies ongoing.

• INCA33989, a monoclonal antibody for MF and ET, is in phase III with a focus on both conventional and composite endpoints; subcutaneous delivery and next-generation antibodies are in development.

• Latarcibart (VGA039) for von Willebrand disease is in phase III, aiming to be the first once-monthly prophylactic, with potential expansion into other bleeding disorders.

• Povorcitinib is expected to launch in 2027 for hidradenitis suppurativa, with additional indications in vitiligo and prurigo nodularis planned.

Market opportunities and commercial strategy

• GI oncology (PDAC and CRC) represents a $7.5–10 billion TAM in the U.S., with G12D and TGF-beta assets positioned for multi-asset, multi-line franchise growth.

• Hematology franchise aims to replicate Jakafi’s success, targeting CALR-mutated MF and ET with INCA33989 and next-gen antibodies, and expanding into V617F mutations through internal and partnered programs.

• Latarcibart’s mechanism could address all types of von Willebrand disease and potentially other bleeding disorders, with a pivotal trial expected to read out in early 2029.

• Povorcitinib is positioned as a first-in-class oral multi-cytokine inhibitor for HS, with a peak sales potential of at least $1 billion and a planned sequencing strategy with OPZELURA.